U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2019
334
Substance Class Protein
Created
by admin
on Wed Apr 02 06:55:14 GMT 2025
Edited
by admin
on Wed Apr 02 06:55:14 GMT 2025
Protein Type MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type IGG1
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
5384HK7574
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
TRASTUZUMAB DERUXTECAN
INN  
USAN   INN  
Official Name English
trastuzumab deruxtecan [INN]
Preferred Name English
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (METASTATIC LYMPH NODE GENE 19 PROTEIN, PROTO-ONCOGENE C-ERBB-2, CD340 ANTIGEN))HUMANIZED MONOCLONAL ANTIBODY CONJUGATED TO DERUXTECAN, A CAMPTOTHECIN DERIVATIVE AND A LI
Systematic Name English
TRASTUZUMAB DERUXTECAN [JAN]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN TYROSINE KINASE RECEPTOR ERBB2) (HUMAN-MUS MUSCULUS MONOCLONAL DS20151130 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL DS20151130 LIGHT CHAIN, DIMER, THIOETHER WITH N-(6-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1
Systematic Name English
TRASTUZUMAB DERUXTECAN [USAN]
Common Name English
Trastuzumab deruxtecan [WHO-DD]
Common Name English
DS-8201
Code English
Classification Tree Code System Code
NCI_THESAURUS C1512
Created by admin on Wed Apr 02 06:55:14 GMT 2025 , Edited by admin on Wed Apr 02 06:55:14 GMT 2025
FDA ORPHAN DRUG 738420
Created by admin on Wed Apr 02 06:55:14 GMT 2025 , Edited by admin on Wed Apr 02 06:55:14 GMT 2025
NCI_THESAURUS C129823
Created by admin on Wed Apr 02 06:55:14 GMT 2025 , Edited by admin on Wed Apr 02 06:55:14 GMT 2025
Code System Code Type Description
FDA UNII
5384HK7574
Created by admin on Wed Apr 02 06:55:14 GMT 2025 , Edited by admin on Wed Apr 02 06:55:14 GMT 2025
PRIMARY
WIKIPEDIA
Trastuzumab deruxtecan
Created by admin on Wed Apr 02 06:55:14 GMT 2025 , Edited by admin on Wed Apr 02 06:55:14 GMT 2025
PRIMARY
NCI_THESAURUS
C152716
Created by admin on Wed Apr 02 06:55:14 GMT 2025 , Edited by admin on Wed Apr 02 06:55:14 GMT 2025
NO STRUCTURE GIVEN
DAILYMED
5384HK7574
Created by admin on Wed Apr 02 06:55:14 GMT 2025 , Edited by admin on Wed Apr 02 06:55:14 GMT 2025
PRIMARY
LACTMED
Trastuzumab Deruxtecan
Created by admin on Wed Apr 02 06:55:14 GMT 2025 , Edited by admin on Wed Apr 02 06:55:14 GMT 2025
PRIMARY
RXCUI
2267582
Created by admin on Wed Apr 02 06:55:14 GMT 2025 , Edited by admin on Wed Apr 02 06:55:14 GMT 2025
PRIMARY
CAS
1826843-81-5
Created by admin on Wed Apr 02 06:55:14 GMT 2025 , Edited by admin on Wed Apr 02 06:55:14 GMT 2025
PRIMARY
USAN
GH-79
Created by admin on Wed Apr 02 06:55:14 GMT 2025 , Edited by admin on Wed Apr 02 06:55:14 GMT 2025
PRIMARY
DRUG BANK
DB14962
Created by admin on Wed Apr 02 06:55:14 GMT 2025 , Edited by admin on Wed Apr 02 06:55:14 GMT 2025
PRIMARY
RXCUI
2267574
Created by admin on Wed Apr 02 06:55:14 GMT 2025 , Edited by admin on Wed Apr 02 06:55:14 GMT 2025
ALTERNATIVE
SMS_ID
100000174462
Created by admin on Wed Apr 02 06:55:14 GMT 2025 , Edited by admin on Wed Apr 02 06:55:14 GMT 2025
PRIMARY
NCI_THESAURUS
C128799
Created by admin on Wed Apr 02 06:55:14 GMT 2025 , Edited by admin on Wed Apr 02 06:55:14 GMT 2025
PRIMARY
INN
10516
Created by admin on Wed Apr 02 06:55:14 GMT 2025 , Edited by admin on Wed Apr 02 06:55:14 GMT 2025
PRIMARY
DRUG CENTRAL
5367
Created by admin on Wed Apr 02 06:55:14 GMT 2025 , Edited by admin on Wed Apr 02 06:55:14 GMT 2025
PRIMARY
From To
2_223 4_214
1_223 3_214
1_22 1_96
1_147 1_203
1_264 1_324
1_370 1_428
2_22 2_96
2_147 2_203
2_264 2_324
2_370 2_428
3_23 3_88
3_134 3_194
4_23 4_88
4_134 4_194
1_229 2_229
1_232 2_232
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_300
N 2_300
Related Record Type Details
FAM-TRASTUZUMAB DERUXTECAN-NXKI
SUB_CONCEPT->SUBSTANCE
DNA TOPOISOMERASE 1
TARGET -> INHIBITOR
Related Record Type Details
TRASTUZUMAB DERUXTECAN
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO ACID SUBSTITUTION C Amount: CYSTEINYL DERUXTECAN I1NS1DHT5R
AMINO ACID REMOVAL [1_450] [2_450] C-TERMINUS Amount: LYSINE K3Z4F929H6
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966